Literature DB >> 15879341

Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.

Mario Di Napoli1, Markus Schwaninger, Roberto Cappelli, Elena Ceccarelli, Giacinto Di Gianfilippo, Cristina Donati, Hedley C A Emsley, Sandro Forconi, Stephen J Hopkins, Luca Masotti, Keith W Muir, Anna Paciucci, Francesca Papa, Sabina Roncacci, Dirk Sander, Kerstin Sander, Craig J Smith, Alessandro Stefanini, Daniela Weber.   

Abstract

BACKGROUND AND
PURPOSE: Several studies have shown, in different populations, that modest elevation of plasma C-reactive protein (CRP) in the range seen in apparently healthy individuals is a strong predictor of future vascular events. Elevated plasma CRP concentrations are also associated with an increased risk of cerebrovascular events and an increased risk of fatal and nonfatal cardiovascular events in ischemic stroke patients. These epidemiological and clinical observations suggest that determination of plasma CRP concentrations could be used as an adjunct for risk assessment in primary and secondary prevention of cerebrovascular disease and be of prognostic value. The aim of this review is to summarize the evidence for CRP as an independent predictor of cerebrovascular events in at-risk individuals and ischemic stroke patients and to consider its usefulness in evaluating prognosis after stroke. SUMMARY OF REVIEW: CRP fulfils most of the requirements of a new risk and prognostic predictor, but several issues await further confirmation and clarification before this marker can be included in the routine evaluation of stroke patients and subjects at risk for cerebrovascular disease. Potentially important associations have been established between elevated plasma CRP concentrations and increased efficacy of established therapies, particularly lipid-lowering therapy with statins.
CONCLUSIONS: At present, there is not sufficient evidence to recommend measurement of CRP in the routine evaluation of cerebrovascular disease risk in primary prevention, because there is insufficient evidence as to whether early detection, or intervention based on detection, improves health outcomes, although shared risk of cardiovascular disease indicates this may be of value. In secondary prevention of stroke, elevated CRP adds to existing prognostic markers, but it remains to be established whether specific therapeutic options can be derived from this.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879341     DOI: 10.1161/01.STR.0000165929.78756.ed

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  104 in total

1.  Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis.

Authors:  Anna Maria Gori; Betti Giusti; Benedetta Piccardi; Patrizia Nencini; Vanessa Palumbo; Mascia Nesi; Antonia Nucera; Giovanni Pracucci; Paolina Tonelli; Eleonora Innocenti; Alice Sereni; Elena Sticchi; Danilo Toni; Paolo Bovi; Mario Guidotti; Maria Rosaria Tola; Domenico Consoli; Giuseppe Micieli; Rossana Tassi; Giovanni Orlandi; Maria Sessa; Francesco Perini; Maria Luisa Delodovici; Maria Luisa Zedde; Francesca Massaro; Rosanna Abbate; Domenico Inzitari
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-07       Impact factor: 6.200

Review 2.  Blood biologic markers of stroke: improved management, reduced cost?

Authors:  Alison E Baird
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

Review 3.  Inflammatory mechanisms of stroke.

Authors:  Mitchell S V Elkind
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 4.  Inflammatory markers and stroke.

Authors:  Mitchell S V Elkind
Journal:  Curr Cardiol Rep       Date:  2009-01       Impact factor: 2.931

5.  Early hyperglycemia and intravenous insulin-the rationale and management of hyperglycemia for spontaneous intracerebral hemorrhage patients: is time for change?

Authors:  Daniel A Godoy; Gustavo R Piñero; Silvana Svampa; Francesca Papa; Mario Di Napoli
Journal:  Neurocrit Care       Date:  2009       Impact factor: 3.210

6.  C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.

Authors:  Mitchell S V Elkind; Jorge M Luna; Leslie A McClure; Yu Zhang; Christopher S Coffey; Ana Roldan; Oscar H Del Brutto; Edwin Javier Pretell; L Creed Pettigrew; Brett C Meyer; Jorge Tapia; Carole White; Oscar R Benavente
Journal:  Stroke       Date:  2014-02-12       Impact factor: 7.914

Review 7.  C-reactive protein and long-term ischemic stroke prognosis.

Authors:  Reyna L VanGilder; Danielle M Davidov; Kyle R Stinehart; Jason D Huber; Ryan C Turner; Karen S Wilson; Eric Haney; Stephen M Davis; Paul D Chantler; Laurie Theeke; Charles L Rosen; Todd J Crocco; Laurie Gutmann; Taura L Barr
Journal:  J Clin Neurosci       Date:  2013-08-23       Impact factor: 1.961

8.  C-reactive protein and aetiological subtypes of cerebral infarction.

Authors:  Alessandro Terruzzi; Laura Valente; Roberto Mariani; Luca Moschini; Massimo Camerlingo
Journal:  Neurol Sci       Date:  2008-09-20       Impact factor: 3.307

9.  Infectious burden and risk of stroke: the northern Manhattan study.

Authors:  Mitchell S V Elkind; Pankajavalli Ramakrishnan; Yeseon P Moon; Bernadette Boden-Albala; Khin M Liu; Steve L Spitalnik; Tanja Rundek; Ralph L Sacco; Myunghee C Paik
Journal:  Arch Neurol       Date:  2009-11-09

Review 10.  Omega-3 fatty acids and cognitive function in women.

Authors:  Jennifer G Robinson; Nkechinyere Ijioma; William Harris
Journal:  Womens Health (Lond)       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.